All Topics

Biocon Limited has commercially launched YESAFILI (aflibercept-jbvf), a biosimilar to Regeneron's EYLEA, in the United States following settlement agreements that lifted previous injunction barriers. This marks the second aflibercept biosimilar available in the U.S. market, entering a competitive landscape where patent litigation continues to shape biosimilar entry strategies. The launch follows a complex legal journey involving multiple jurisdictions and settlement negotiations that ultimately permitted ea

Pennsylvania Governor Josh Shapiro's Executive Order introduces new regulations for data center development, establishing requirements for energy affordability, community engagement, and environmental protection while granting municipalities increased authority over local projects. The order presents unique challenges for developers as most local codes lack provisions for data centers, a relatively new land use category that has emerged only in recent years.

Global competition authorities in Q2 2026 delivered a spectrum of enforcement outcomes—from unconditional clearances to structural remedies and deal abandonment—across media, construction, digital services, defense, and visual-content markets. Federal clearance no longer shields transactions from parallel state or private enforcement, while European regulators increasingly weigh competitive pressure from digital platforms and generative AI. The quarter underscores that commercial arrangements ma